114
Participants
Start Date
March 11, 2016
Primary Completion Date
February 21, 2022
Study Completion Date
February 21, 2022
MSB0011359C
Subjects with metastatic or locally advanced solid tumors received intravenous infusion of MSB0011359C over 1 hour once every two weeks for up to 12 months until confirmed progressive disease (PD), unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product (IMP) occurs.
NHO Kyushu Cancer Center, Fukuoka
National Cancer Center East, Department of Experimental Therapeutics, Kashiwa
National Cancer Center East, Department of hepatobiliary and pancreatic oncology, Kashiwa
Saitama Cancer Center, Kitaadachi-gun
NHO Shikoku Cancer Center, Matsuyama
Aichi Cancer Center Hospital, Nagoya
Kinki University Hospital, Sayama
National Cancer Center, Department of Experimental Therapeutics, Tokyo
National Cancer Center, Department of hepatobiliary and pancreatic oncology, Tokyo
Kanagawa Cancer Center, Department of Gastroenterology, Yokohama
Kanagawa Cancer Center, Department of Gastrointestinal Surgery, Yokohama
Asan Medical Center, Seoul
Seoul National University Hospital, Seoul
Severance Hospital, Seoul
National Cheng Kung University Hospital, Tainan City
Mackay Memorial Hospital, Taipei
National Taiwan University Hospital, Taipei
Chang Gung Memorial Hospital; Linkou, Taoyuan District
Merck KGaA, Darmstadt, Germany
INDUSTRY